BioSpace News Archive

Keiretsu Forum announced today that OtoNexus Medical Technologies was named ‘Most Valued Company’ at the virtual Keiretsu Forum Investor Capital Expo. Keiretsu Forum is the world’s largest angel investor n

Manhattan Scientifics Inc. (MHTX: OTCQB) provides a 45-minute interview with Imagion Biosystems Chairman/CEO Bob Proulx describing the very-early-cancer-diagnostic development that MHTX incubated and helped to go public on the Australian stock exchange: IMAGION BIOSYSTEMS LTD.

Silverback Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer and other serious diseases, today announced the appointment of Jonathan Piaz

Enzolytics, Inc. (OTC PINK:ENZC) or the “Company” announced the appointment of Ronald Moss, M.D., to the Medical Advisory Board of the Company. Dr. Moss has an extensive 25-year background as an executive with numerous Biotechnology companies including direct clinical experience. He has a respected history of leveraging leadership, analytical analysis and clinical experience t

American Gene Technologies (AGT) announced today that the first trial participant was enrolled in the Phase 1 trial of AGT103-T , a new cell and gene therapy for HIV disease. The first trial participant underwent leukapheresis, a procedure for obtaining concentrated white blood cells, which will be used for manufacturing the AGT103-T cell product. After manufacturing and required safety testing, the product will be infused back into the tr

Strategic hires to its senior leadership team include former AWS executives to oversee product and engineering strategy

Bioventus to Provide CVS Caremark ® with its Portfolio of Preferred Options for Knee Osteoarthritis Patients Seeking Pain Relief

NightWare, a medical device company focused on treating people with nightmares related to post-traumatic stress disorder (PTSD) and other traumatic events, has announced it has received U.S. Food and Drug Administration (FDA) marketing permission for the NightWare™ therapeutic platform. NightWare is the first and only medical device to be indicated for the temporary reduction of sleep disturbance related to nightmares in adu

In partnership with renowned imaging research center, Neuro42 to commercialize technology that helps physicians triage patients with neurological diseases and injuries sooner

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that will participate in the H.C. Wainwright 6 th Annual Israel Conference on November 12 th , 2020. H.C. Wainwright 6th Annual Israel Conference – Thursday November 12, 2020 Presentation Time : 3:30pm Weblink : https://journey.ct.events